Key points are not available for this paper at this time.
Targeting tumor metabolic remodeling offers a promising strategy to overcome immune resistance and improve the therapeutic efficacy of immunotherapy in lung cancer. Continued efforts to elucidate the molecular mechanisms linking metabolism and immunity may pave the way for novel combination therapies with durable clinical benefits.
Chen et al. (2025) studied this question.